Immediate and Long-term Hemodynamic and Clinical Effects of Sildenafil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy
- 1 October 2003
- journal article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 78 (10) , 1207-1213
- https://doi.org/10.4065/78.10.1207
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiologyJournal of the American College of Cardiology, 2000
- Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin AnalogueNew England Journal of Medicine, 2000
- Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of DiseaseAnnals of Internal Medicine, 2000
- Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled TrialAnnals of Internal Medicine, 2000
- Inhaled nitric oxide in primary pulmonary hypertensionJournal of the American College of Cardiology, 1998
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantationJournal of the American College of Cardiology, 1995
- Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.American Journal of Respiratory and Critical Care Medicine, 1995